Treatment News : Five-Drug Cocktail Fights HIV Reservoir During Acute Infection

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 2, 2013

Five-Drug Cocktail Fights HIV Reservoir During Acute Infection

Preliminary findings of a research study involving a five-drug antiretroviral (ARV) cocktail have found that people who start the therapy during acute (or very early) infection experience a marked drop in viral DNA integrated into cells when compared with those living with HIV for some time before beginning the intensified cocktail, MedPage Today reports. Eva Wolf, PhD, of MUC Research in Munich, Germany, presented these two-year results of a seven-year prospective trial at the 7th International AIDS Society (IAS) Meeting in Kuala Lumpur.

While the findings suggest that such a cocktail may help lead to a functional cure by preventing the establishment of the HIV reservoir, the study did not compare a five-drug regimen with the standard three-drug cocktail. So no conclusions can be drawn about whether five drugs would more effectively lead to a functional cure or viral remission. Recently, a study of a group known as the Visconti cohort found that 14 people with HIV in France were able to achieve viral remission after initiating ARVs during acute infection and remaining on the drugs for a median three years before terminating treatment.

The five-drug study recruited 20 participants with acute HIV infection and gave them a regimen of two nucleoside reverse transcriptase inhibitors, a protease inhibitor, the entry inhibitor Selzentry (maraviroc) and the integrase inhibitor Isentress (raltegravir). Investigators also recruited 20 people with longtime HIV infection and gave them Selzentry and Isentress in addition to their regular three-drug regimen.

Two years into the study, the chronic participants essentially had no change in their proviral DNA, which is considered to be a part of the reservoir. The primary infection group saw a median drop of 25 copies per million cells.

Experts not involved in the study criticized it for not comparing three-drug regimens with five-drug regimens and told MedPage Today that prior research has shown that an intensified drug regimen does not have a clear benefit.

To see the IAS poster, click here.

To read the MedPage Today story, click here.

Search: HIV, five-drug cocktail, antiretrovirals, ARVs, 7th International AIDS Society Meeting in Kuala Lumpur, IAS, Eva Wolf, MedPage Today, Selzentry, maraviroc, Isentress, raltegravir, proviral DNA, reservoir.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.